PT2385 (PT-2385) is a nove, potent, selective and orally bioactive inhibitor of hypoxia inducible factor (HIF-2α) with anticancer and anti-hepatic steatosis activity.

Molidustat (formerly known as BAY 85-3934) is a novel potent inhibitor of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) which stimulates erythropoietin (EPO) production and the formation of red blood cells.

LW6 is a hypoxia-inducible factor 1 (HIF) inhibitor which potently inhibits HIF-1α accumulation by degrading HIF-1α without affecting the HIF-1a mRNA levels during hypoxia.

Oroxylin A is a novel and potent flavonoid.

Amifostine trihydrate (WR2721), a phosphorylated aminosulfhydryl compound, is the first approved radioprotective drug, it is used to decrease the risk of kidney problems caused by treatment with cisplatin.

Enarodustat (formerly JTZ-951; JTZ951; Enaroy) is an orally bioactive hypoxia inducible factor-proly hydroxylase (HIF-PH) inhibitor approved (in 2020) in Japan for the treatment of anemia associated with chronic kidney disease (CKD).

Chlorogenic acid (3-O-Caffeoylquinic acid; Heriguard; NSC-407296) is a naturally occuring phenolic compound found in coffee and tea.

Daprodustat (formerly known as GSK1278863; Duvroq) is a novel orally bioavailable hypoxia-inducible factor prolyl hydroxylase (HIF-PHI) inhibitor that has been approved for treatment of anemia associated with CKD/chronic kidney disease.

Vadadustat (formerly AKB-6548; PG-1016548; B-506; AKB6548; PG1016548; Vafseo) is a novel, potent, titratable and orally bioavailable hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor with the potential for the treatment of anemia.

Belzutifan (PT-2977; MK-6482; PT2977; MK6482; Welireg) is a novel, selective and orally bioavailable HIF-2α (hypoxia-inducible factor 2α) inhibitor that has gained FDA approval in 2021 for the treatment of von Hippel–Lindau disease-associated renal cell carcinoma.